Developer docs
API playgroundTry for free, no card

Search company profiles

GC Lymphotec

Full company profile

uuid000llv8

Namestring
GC Lymphotec
Legal namestring
株式会社GCリンフォテック (GC LYMPHOTEC Inc.)
Websiteurl
lymphotec.co.jp
Company typeenum
Private
Founded yearint
1999
Descriptiontext

GC Lymphotec is a Tokyo-based cell therapy company founded in 1999 by Dr. Sekine to commercialize the activated autologous lymphocyte culture method (the "Sekine Method") originally developed at Japan's National Cancer Center. Operating as a vertically integrated cell therapy platform, the company provides contract manufacturing (CMO) of immune cells (T cells, NK cells, MSC) for medical institutions, quality control testing services (CAS), proprietary cell culture reagents (BAMBANKER cryopreservation solutions and iMediam media), and AI-powered cancer genetic testing (ai-CANCERCH for screening, DNA CT for recurrence monitoring). The company serves hospitals, oncology clinics, regenerative medicine centers, and biotech research institutions across Japan and selected international markets, with 4,000+ Japanese patient cases treated over 25+ years and an affiliated network of 20+ medical institutions across the country.

The company's core technology is anchored by the Sekine Method, a solid-phase CD3 antibody culture technique that achieves up to 50,000-fold T cell expansion in two weeks — vastly exceeding conventional IL-2-only methods (10-100x). This platform is protected by eight granted Japanese patents covering memory T cell culture (Patent No. 6142142), serum-free culture medium (Patent No. 7144872), transport cryopreservation (Patent No. 6671582), mycoplasma detection, ozone incubator sterilization, and DHEA-S pharmaceutical preparation. Manufacturing is conducted under GMP-compliant environments with ISO 9001 certification and a Specific Cell Processing Product Manufacturing License (obtained June 4, 2015, facility FA3150003) under Japan's Act on the Safety of Regenerative Medicine. The BAMBANKER cryopreservation product line has been sold for over 20 years, and the genetic testing products leverage AI-powered cfDNA/ctDNA analysis with peer-reviewed validation in Nature Communications, Cancer Research, Scientific Reports, AJG, and Clinical Chemistry.

GC Lymphotec monetizes through multiple revenue streams: per-batch CMO contracts with medical institutions, per-test CAS fees, unit sales of BAMBANKER and iMediam products through distributors (Fujifilm Wako Pure Chemical, Japan Genetics, Cosmo Bio), per-test fees for ai-CANCERCH and DNA CT through affiliated clinics, and technology licensing to international partners including GC Cell Corporation (Korea, 2005, producing the approved product Immuncell-LC which received US FDA Orphan Drug Designation in 2018) and a Taiwanese biomedical group (大中國際生醫集團, 2014). The company is a privately held subsidiary of Korea's GC Group (GC Green Cross, founded 1967), a major pharmaceutical conglomerate with operations in Korea, Japan, the United States, and Brazil. As of September 2024, Han Jun-hee serves as Representative Director and President.

Short descriptiontext

GC Lymphotec is a Tokyo-based cell therapy company providing contract manufacturing of immune cells, AI-powered cancer genetic testing via liquid biopsy, and proprietary cell culture reagents to medical institutions and biotech clients across Japan and selected international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersKoto, Japan
HQ citystring
Koto
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, cancer immunotherapy services, cryopreservation solutions, regenerative medicine CDMO, liquid biopsy testing
Industry3 codes
PRIMARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
Product category
Cell Therapy and Regenerative Medicine CDMO
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model7 records
1CMO — Cell Culture Contract Manufacturing
TypeProfessional Services
Description

Contract manufacturing services for immune cells (T cells, NK cells, MSC) as 'specified cell processed products' under Japan's Regenerative Medicine Safety Act. The company holds a cell processing permit (obtained June 4, 2015, facility number FA3150003) and manufactures cell therapy products for client medical institutions. Provides fresh and frozen/thawed formats. Generates revenue on a per-batch/per-treatment-course basis.

lymphotec.co.jp
2CAS — Contract Testing Services
TypeProfessional Services
Description

Quality control testing services for cell products including: sterility testing (membrane filter method, SCD agar culture method), endotoxin testing (end-point colorimetric assay), flow cytometry analysis (multicolor using Beckman-Coulter CytoFLEX), pH measurement, osmolality measurement, and mycoplasma testing. Provided to pharmaceutical companies, research institutions, and cell therapy developers on a per-test fee basis.

lymphotec.co.jp
3BAMBANKER Cryopreservation Solution Sales
TypeHardware Sales
Description

Sale of proprietary cell cryopreservation solutions under the BAMBANKER brand. Products sold directly and through distributors (Japan Genetics, Cosmo Bio, Fujifilm Wako Pure Chemical) domestically and internationally. Includes BAMBANKER, BAMBANKER Direct, BAMBANKER hRM (exclusive distribution by Japan Genetics), BAMBANKER DMSO free, and BAMBANKER iStock. Revenue from product sales on a per-unit basis.

lymphotec.co.jp
4iMediam Culture Medium Sales
TypeHardware Sales
Description

Sale of proprietary cell culture media (iMediam™ for T). Sold domestically in Japan and exported to Korea, China, Taiwan, and other markets. In Korea, the medium is used in the manufacture of cell therapy pharmaceuticals; in Taiwan it is used in clinical trials. Custom small-batch manufacturing also offered. Revenue on a per-unit/product basis.

lymphotec.co.jp
5ai-CANCERCH Genetic Testing
TypeProfessional Services
Description

Cancer early detection screening test using AI-based ctDNA analysis. Offered through affiliated medical institutions across Japan. Results delivered in 2–4 weeks. Includes free follow-up care program for positive results. Revenue generated per test through medical institutions.

lymphotec.co.jp
6DNA CT Cancer Monitoring
TypeProfessional Services
Description

Cancer recurrence monitoring test using ctDNA/NGS/AI for post-treatment cancer patients. Provided as an ongoing monitoring service through affiliated medical institutions. Revenue per test basis through the clinic network.

lymphotec.co.jp
7Technology Licensing
TypeLicensing Royalties
Description

Licensing of activated autologous lymphocyte culture technology to international partners. Korean licensing to GC Cell Corporation (2005) resulted in the approved product 'Immuncell-LC' and subsequent US FDA Orphan Drug Designation (2018). Taiwan licensing to 大中国際生医集団 (2014). Generates upfront fees and potentially ongoing royalties.

lymphotec.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details4 tiers
1Cell therapy manufacturing (T cells, NK cells, MSC) — pricing not publicly disclosed, quote-based per batch/course
ModelOtherBilling cadenceMulti-year contract
Notes

Cell therapy manufacturing services are custom/quote-based. Pricing depends on cell type, number of doses, fresh vs. frozen format, and patient-specific requirements. Billed per batch or per treatment course.

lymphotec.co.jp
2Contract testing services (sterility, endotoxin, flow cytometry, pH, osmolality, mycoplasma) — pricing not publicly disclosed, quote-based per test
ModelOtherBilling cadencePay-as-you-go
Notes

Testing services are quote-based. Contact: sales@lymphotec.co.jp or 03-3630-2530. Pricing varies by sample type, number of tests, and turnaround requirements.

lymphotec.co.jp
3BAMBANKER cryopreservation solutions and iMediam culture media — pricing not publicly disclosed, available through distributors or direct purchase
ModelUnit PricingBilling cadencePay-as-you-go
Notes

BAMBANKER products sold through distributors (Japan Genetics, Cosmo Bio, Fujifilm Wako Pure Chemical) and directly. Unit pricing not publicly listed. Contact sales for quotes.

lymphotec.co.jp
4ai-CANCERCH cancer screening — pricing determined through medical institutions; care program (follow-up tests) is provided free of charge
ModelOtherBilling cadencePay-as-you-go
Notes

Test ordered through affiliated medical institutions. Results in 2–4 weeks. Free follow-up care program (up to 6 additional tests over 2 years) for patients with 'Watchful' or 'Intensive' management results. Mutation profiling available for intensive management patients at additional cost.

lymphotec.co.jp
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1BAMBANKER
Description

Series of cell cryopreservation solutions including BAMBANKER, BAMBANKER Direct, BAMBANKER hRM, BAMBANKER DMSO free, and BAMBANKER iStock with over 20 years of sales history.

lymphotec.co.jp
+3 more records
Core offering1 text field

GC Lymphotec provides contract cell therapy manufacturing (CMO) and contract quality control testing (CAS) for immune cell products, alongside proprietary cell culture reagents (BAMBANKER cryopreservation solutions, iMediam culture medium) and AI-powered cancer genetic tests (ai-CANCERCH screening, DNA CT monitoring). Services target medical institutions, biotech companies, and research organizations, with international technology licensing to Korea (GC Cell) and Taiwan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • T cell expansion of up to 50,000-fold in 2 weeks using the Sekine Method (vs. 10-100x for conventional IL-2 methods)
+8 more records
Product overview1 text field

GC Lymphotec is a cell therapy company providing a comprehensive portfolio of products and services for cancer treatment and regenerative medicine. The core offerings include CMO (contracted cell culture services) for T cells, NK cells, and MSC; CAS (contracted testing services) for quality control; and genetic testing services (ai-CANCERCH for cancer screening and DNA CT for monitoring). The product portfolio includes BAMBANKER cryopreservation solutions (BAMBANKER, BAMBANKER Direct, BAMBANKER hRM, BAMBANKER DMSO free, BAMBANKER iStock) and iMediam culture medium, all manufactured under GMP and ISO 9001 standards. The company pioneered the Sekine method for activated autologous lymphocyte therapy and has licensed its technology internationally, including approval of Immuncell-LC in Korea and FDA orphan drug designation in the US.

Product and service13 records
1CMO (Contract Manufacturing Organization) Services
CategoryContract Cell Therapy Manufacturing
Description

Contracted cell culture and processing services for T cells, NK cells, and MSC including activated autologous lymphocyte therapy using the proprietary Sekine Method technology. Provided to medical institutions for cancer immunotherapy and regenerative medicine, with 25+ years of experience and 4,000+ patient cases.

2CAS (Contract Testing Services)
CategoryContract Quality Control Testing
Description

Contracted quality control testing services including sterility testing (membrane filter, SCD agar culture), endotoxin testing (end-point colorimetric assay), flow cytometry analysis (Beckman-Coulter CytoFLEX), pH measurement, osmolality measurement, and mycoplasma testing. Provided to pharmaceutical companies, research institutions, and cell therapy developers using GMP-compliant facilities.

3ai-CANCERCH Cancer Screening
CategoryCancer Genetic Testing
Description

AI-powered cancer early detection screening test using cfDNA/ctDNA analysis from a single blood draw. Uses Low Coverage Whole Genome Sequencing (NGS) combined with AI analysis to screen for 10 cancer types with results delivered in 2-4 weeks. Includes free follow-up care program (up to 6 additional tests over 2 years) for positive results.

4DNA CT Cancer Monitoring
CategoryCancer Genetic Testing
Description

Cancer monitoring test for recurrence and metastasis detection using ctDNA analysis via NGS and AI algorithms. Enables ongoing disease surveillance for post-treatment cancer patients by detecting cancer cell-derived cfDNA in blood, identifying recurrence before imaging can.

5iNK Therapy
CategoryCell Therapy Service
Description

Immunotherapy using induced NK (iNK) cells specifically proliferated using proprietary T cell processing technology, allowing multiple treatments from a single blood draw with frozen storage. Offered in fresh format to medical institutions.

6MSC (Mesenchymal Stem Cell) Culture Services
CategoryRegenerative Medicine Service
Description

Mesenchymal stem cell culture services using serum-free proprietary medium for regenerative medicine applications, including treatments for chronic pain and joint conditions. Provided to medical institutions as contract manufacturing service.

7BAMBANKER (Original)
CategoryCell Cryopreservation Reagent
Description

Original cell cryopreservation solution with 20+ years of market history. Serum-free formulation with no lot-to-lot variation, manufactured under GMP-compliant environment with ISO 9001 certified quality management. Sold domestically and internationally.

8BAMBANKER Direct
CategoryCell Cryopreservation Reagent
Description

Cryopreservation solution allowing direct freezing without removing culture supernatant, simplifying the cell freezing workflow.

9BAMBANKER hRM
CategoryCell Cryopreservation Reagent
Description

Cryopreservation solution for human ES/iPS cell research containing only pharmaceutical-grade albumin. Exclusively distributed by Japan Genetics Co., Ltd.

10BAMBANKER DMSO free
CategoryCell Cryopreservation Reagent
Description

DMSO-free cryopreservation solution for users who wish to avoid DMSO exposure.

11BAMBANKER iStock
CategoryCell Cryopreservation Reagent
Description

Cryopreservation solution with confirmed Regenerative Medicine Product Material Eligibility, designed for use as raw material in regenerative medicine product manufacturing.

12iMediam for T
CategoryCell Culture Medium
Description

Proprietary serum-free culture medium for efficient expansion of T cells and NK cells using patented technology (Patent No. 7144872). Has obtained Regenerative Medicine Product Material Qualification Confirmation. Manufactured under ISO 9001 quality management. Sold in Japan and exported to Korea, China, Taiwan. Used in Korean cell therapy pharmaceutical manufacturing and Taiwan clinical trials.

13Activated Autologous Lymphocyte Therapy (Sekine Method)
CategoryCancer Immunotherapy Service
Description

Cancer immunotherapy using the proprietary Sekine Method developed by Dr. Sekine at the National Cancer Center, involving T cell activation and expansion up to 50,000-fold using solid-phase CD3 antibody (OKT3). Composed of two phases: activation culture with OKT3 immobilized on vessel surface, followed by amplification culture. T cells retain cytotoxic activity against tumor cells. Over 4,000 patients treated in Japan over 25+ years.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1大中国際生醫集団 (Da Zhong International Biomedical Group, Taiwan)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-01-01
Description

In 2014, GC Lymphotec entered into a technology licensing agreement with Taiwan's 大中国際生醫集団 for the technology transfer of activated autologous lymphocyte culture. The partnership enables the Taiwanese partner to manufacture and commercialize cell therapy products using GC Lymphotec's proprietary culture technology.

lymphotec.co.jp
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2005-01-01
Description

GC Lymphotec licensed its activated autologous lymphocyte culture technology to GC Cell Corporation in 2005. GC Cell used this technology to develop 'Immuncell-LC,' which received approval from the Korean Ministry of Food and Drug Safety (MFDS) in 2007 for hepatocellular carcinoma. The product also received US FDA Orphan Drug Designation in 2018. GC Cell has manufactured 80,000+ cumulative doses and treated 12,000+ patients in Korea. This is the company's flagship international licensing partnership and core source of overseas validation.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Major sales distributor for GC Lymphotec's cell culture reagents and cryopreservation solutions. Listed as one of the main sales channels alongside Japan Genetics and Cosmo Bio.

4Japan Genetics Co., Ltd.
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for BAMBANKER hRM (human ES/iPS research cryopreservation solution). Listed as one of the main sales channels alongside Fujifilm Wako Pure Chemical and Cosmo Bio.

lymphotec.co.jp
5Cosmo Bio Co., Ltd.
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Major sales distributor for GC Lymphotec's cell culture reagents and cryopreservation solutions. Listed as one of the main sales channels alongside Fujifilm Wako Pure Chemical and Japan Genetics.

lymphotec.co.jp
Strategic tierCoreTypeStrategic or Co-development Partner
Description

GC Lymphotec is a subsidiary of the GC Group (GC Green Cross), founded in 1967 and headquartered in Korea. GC Group is a leading Korean pharmaceutical company engaged in blood products, biopharmaceuticals, vaccines, diagnostics, and regenerative medicine. GC Group has subsidiaries in Korea, Japan, the United States, and Brazil, and actively serves markets in Asia, Middle East, and North/South America.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese cell therapy CMO/CDMO offering immune cell processing services (T cells, NK cells, dendritic cells) for cancer immunotherapy under Japan's Regenerative Medicine Safety Act. Directly comparable in business model — autologous cell therapy manufacturing for affiliated Japanese clinics.

TypeDirect peer
Description

GC Lymphotec's Korean licensee and GC Group sibling company. Commercializes Immuncell-LC using licensed Sekine Method technology. Most directly comparable as a cell therapy product company using GC Lymphotec's own IP, providing reference economics for licensing validation.

3Takara Bio Inc.
TypeBroad incumbent
Description

Japanese biotech with cell therapy, regenerative medicine, and cell processing reagent offerings. Comparable in cell culture media, cryopreservation reagents, and adjacent cell therapy services — overlaps with BAMBANKER and iMediam product lines.

TypeBroad incumbent
Description

Japanese specialty biopharma with regenerative medicine and cell therapy pipeline. Comparable as a Japan-domiciled player operating in adjacent cell/biologic therapy markets with GMP manufacturing capabilities.

TypeEmerging player
Description

Japanese regenerative medicine company developing stem cell-based therapies (PELICAN). Comparable as a Japan-based, Japan-Regenerative-Medicine-Act-regulated cell therapy developer competing for similar affiliated clinic distribution.

6Resonac Holdings (formerly Hitachi Chemical, Showa Denko Materials)
TypeBroad incumbent
Description

Operates one of Japan's largest regenerative medicine CDMO businesses (formerly Hitachi Chemical Advanced Therapeutics Solutions). Comparable as a cell therapy contract manufacturer targeting the same Japanese regenerative medicine regulatory framework.

TypeBroad incumbent
Description

Global leader in cell and gene therapy CDMO services. Comparable as a high-end cell therapy manufacturing services provider; provides benchmark for international CMO economics, scale, and pricing.

TypeDirect peer
Description

Global leader in cell culture media, cryopreservation reagents (CryoStor, mFreSR), and stem cell research products. Directly comparable to GC Lymphotec's BAMBANKER and iMediam reagent product lines.

TypeBroad incumbent
Description

Cell therapy manufacturing platform provider offering instruments, reagents, and GMP cell processing services. Comparable as a vertically integrated cell therapy manufacturing and reagent supplier serving CAR-T and NK cell developers globally.

10Nikon CeLL innovation Co., Ltd.
TypeEmerging player
Description

Nikon Group's cell therapy and regenerative medicine subsidiary operating GMP cell processing facilities in Japan. Comparable as a Japan-based cell therapy CMO with GMP manufacturing capacity targeting cancer immunotherapy and regenerative medicine.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GC Lymphotec

Cell Therapy and Regenerative Medicine CDMOlymphotec.co.jp

GC Lymphotec is a Tokyo-based cell therapy company providing contract manufacturing of immune cells, AI-powered cancer genetic testing via liquid biopsy, and proprietary cell culture reagents to medical institutions and biotech clients across Japan and selected international markets.

What GC Lymphotec does

GC Lymphotec is a Tokyo-based cell therapy company founded in 1999 by Dr. Sekine to commercialize the activated autologous lymphocyte culture method (the "Sekine Method") originally developed at Japan's National Cancer Center. Operating as a vertically integrated cell therapy platform, the company provides contract manufacturing (CMO) of immune cells (T cells, NK cells, MSC) for medical institutions, quality control testing services (CAS), proprietary cell culture reagents (BAMBANKER cryopreservation solutions and iMediam media), and AI-powered cancer genetic testing (ai-CANCERCH for screening, DNA CT for recurrence monitoring). The company serves hospitals, oncology clinics, regenerative medicine centers, and biotech research institutions across Japan and selected international markets, with 4,000+ Japanese patient cases treated over 25+ years and an affiliated network of 20+ medical institutions across the country.

The company's core technology is anchored by the Sekine Method, a solid-phase CD3 antibody culture technique that achieves up to 50,000-fold T cell expansion in two weeks — vastly exceeding conventional IL-2-only methods (10-100x). This platform is protected by eight granted Japanese patents covering memory T cell culture (Patent No. 6142142), serum-free culture medium (Patent No. 7144872), transport cryopreservation (Patent No. 6671582), mycoplasma detection, ozone incubator sterilization, and DHEA-S pharmaceutical preparation. Manufacturing is conducted under GMP-compliant environments with ISO 9001 certification and a Specific Cell Processing Product Manufacturing License (obtained June 4, 2015, facility FA3150003) under Japan's Act on the Safety of Regenerative Medicine. The BAMBANKER cryopreservation product line has been sold for over 20 years, and the genetic testing products leverage AI-powered cfDNA/ctDNA analysis with peer-reviewed validation in Nature Communications, Cancer Research, Scientific Reports, AJG, and Clinical Chemistry.

GC Lymphotec monetizes through multiple revenue streams: per-batch CMO contracts with medical institutions, per-test CAS fees, unit sales of BAMBANKER and iMediam products through distributors (Fujifilm Wako Pure Chemical, Japan Genetics, Cosmo Bio), per-test fees for ai-CANCERCH and DNA CT through affiliated clinics, and technology licensing to international partners including GC Cell Corporation (Korea, 2005, producing the approved product Immuncell-LC which received US FDA Orphan Drug Designation in 2018) and a Taiwanese biomedical group (大中國際生醫集團, 2014). The company is a privately held subsidiary of Korea's GC Group (GC Green Cross, founded 1967), a major pharmaceutical conglomerate with operations in Korea, Japan, the United States, and Brazil. As of September 2024, Han Jun-hee serves as Representative Director and President.

GC Lymphotec firmographics

Firmographics
Name
GC Lymphotec
Legal name
株式会社GCリンフォテック (GC LYMPHOTEC Inc.)
Website
https://lymphotec.co.jp
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
251–500 employees
Short description
GC Lymphotec is a Tokyo-based cell therapy company providing contract manufacturing of immune cells, AI-powered cancer genetic testing via liquid biopsy, and proprietary cell culture reagents to medical institutions and biotech clients across Japan and selected international markets.
Ownership category
akta.pro rank

GC Lymphotec industry classification

Industry
Product category
Cell Therapy and Regenerative Medicine CDMO
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Cell therapy manufacturing
  • Cancer immunotherapy services
  • Cryopreservation solutions
  • Regenerative medicine CDMO
  • Liquid biopsy testing

Where GC Lymphotec is headquartered

Location

Headquarters

HQ city
Koto
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

GC Lymphotec business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. CMO — Cell Culture Contract Manufacturing: Contract manufacturing services for immune cells (T cells, NK cells, MSC) as 'specified cell processed products' under Japan's Regenerative Medicine Safety Act. The company holds a cell processing permit (obtained June 4, 2015, facility number FA3150003) and manufactures cell therapy products for client medical institutions. Provides fresh and frozen/thawed formats. Generates revenue on a per-batch/per-treatment-course basis.
  2. CAS — Contract Testing Services: Quality control testing services for cell products including: sterility testing (membrane filter method, SCD agar culture method), endotoxin testing (end-point colorimetric assay), flow cytometry analysis (multicolor using Beckman-Coulter CytoFLEX), pH measurement, osmolality measurement, and mycoplasma testing. Provided to pharmaceutical companies, research institutions, and cell therapy developers on a per-test fee basis.
  3. BAMBANKER Cryopreservation Solution Sales: Sale of proprietary cell cryopreservation solutions under the BAMBANKER brand. Products sold directly and through distributors (Japan Genetics, Cosmo Bio, Fujifilm Wako Pure Chemical) domestically and internationally. Includes BAMBANKER, BAMBANKER Direct, BAMBANKER hRM (exclusive distribution by Japan Genetics), BAMBANKER DMSO free, and BAMBANKER iStock. Revenue from product sales on a per-unit basis.
  4. iMediam Culture Medium Sales: Sale of proprietary cell culture media (iMediam™ for T). Sold domestically in Japan and exported to Korea, China, Taiwan, and other markets. In Korea, the medium is used in the manufacture of cell therapy pharmaceuticals; in Taiwan it is used in clinical trials. Custom small-batch manufacturing also offered. Revenue on a per-unit/product basis.
  5. ai-CANCERCH Genetic Testing: Cancer early detection screening test using AI-based ctDNA analysis. Offered through affiliated medical institutions across Japan. Results delivered in 2–4 weeks. Includes free follow-up care program for positive results. Revenue generated per test through medical institutions.
  6. DNA CT Cancer Monitoring: Cancer recurrence monitoring test using ctDNA/NGS/AI for post-treatment cancer patients. Provided as an ongoing monitoring service through affiliated medical institutions. Revenue per test basis through the clinic network.
  7. Technology Licensing: Licensing of activated autologous lymphocyte culture technology to international partners. Korean licensing to GC Cell Corporation (2005) resulted in the approved product 'Immuncell-LC' and subsequent US FDA Orphan Drug Designation (2018). Taiwan licensing to 大中国際生医集団 (2014). Generates upfront fees and potentially ongoing royalties.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCell therapy manufacturing (T cells, NK cells, MSC) — pricing not publicly disclosed, quote-based per batch/course
OtherPay-as-you-goContract testing services (sterility, endotoxin, flow cytometry, pH, osmolality, mycoplasma) — pricing not publicly disclosed, quote-based per test
Unit PricingPay-as-you-goBAMBANKER cryopreservation solutions and iMediam culture media — pricing not publicly disclosed, available through distributors or direct purchase
OtherPay-as-you-goai-CANCERCH cancer screening — pricing determined through medical institutions; care program (follow-up tests) is provided free of charge

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

GC Lymphotec product offering

Product offering

Core offering

GC Lymphotec provides contract cell therapy manufacturing (CMO) and contract quality control testing (CAS) for immune cell products, alongside proprietary cell culture reagents (BAMBANKER cryopreservation solutions, iMediam culture medium) and AI-powered cancer genetic tests (ai-CANCERCH screening, DNA CT monitoring). Services target medical institutions, biotech companies, and research organizations, with international technology licensing to Korea (GC Cell) and Taiwan.

Product overview

GC Lymphotec is a cell therapy company providing a comprehensive portfolio of products and services for cancer treatment and regenerative medicine. The core offerings include CMO (contracted cell culture services) for T cells, NK cells, and MSC; CAS (contracted testing services) for quality control; and genetic testing services (ai-CANCERCH for cancer screening and DNA CT for monitoring). The product portfolio includes BAMBANKER cryopreservation solutions (BAMBANKER, BAMBANKER Direct, BAMBANKER hRM, BAMBANKER DMSO free, BAMBANKER iStock) and iMediam culture medium, all manufactured under GMP and ISO 9001 standards. The company pioneered the Sekine method for activated autologous lymphocyte therapy and has licensed its technology internationally, including approval of Immuncell-LC in Korea and FDA orphan drug designation in the US.

Differentiator

Problem solved

Functional benefit

Brands

  • BAMBANKER: Series of cell cryopreservation solutions including BAMBANKER, BAMBANKER Direct, BAMBANKER hRM, BAMBANKER DMSO free, and BAMBANKER iStock with over 20 years of sales history.
  • iMediam
  • ai-CANCERCH
  • DNA CT

Products and services

  • CMO (Contract Manufacturing Organization) Services Contracted cell culture and processing services for T cells, NK cells, and MSC including activated autologous lymphocyte therapy using the proprietary Sekine Method technology. Provided to medical institutions for cancer immunotherapy and regenerative medicine, with 25+ years of experience and 4,000+ patient cases.
  • CAS (Contract Testing Services) Contracted quality control testing services including sterility testing (membrane filter, SCD agar culture), endotoxin testing (end-point colorimetric assay), flow cytometry analysis (Beckman-Coulter CytoFLEX), pH measurement, osmolality measurement, and mycoplasma testing. Provided to pharmaceutical companies, research institutions, and cell therapy developers using GMP-compliant facilities.
  • ai-CANCERCH Cancer Screening AI-powered cancer early detection screening test using cfDNA/ctDNA analysis from a single blood draw. Uses Low Coverage Whole Genome Sequencing (NGS) combined with AI analysis to screen for 10 cancer types with results delivered in 2-4 weeks. Includes free follow-up care program (up to 6 additional tests over 2 years) for positive results.
  • DNA CT Cancer Monitoring Cancer monitoring test for recurrence and metastasis detection using ctDNA analysis via NGS and AI algorithms. Enables ongoing disease surveillance for post-treatment cancer patients by detecting cancer cell-derived cfDNA in blood, identifying recurrence before imaging can.
  • iNK Therapy Immunotherapy using induced NK (iNK) cells specifically proliferated using proprietary T cell processing technology, allowing multiple treatments from a single blood draw with frozen storage. Offered in fresh format to medical institutions.
  • MSC (Mesenchymal Stem Cell) Culture Services Mesenchymal stem cell culture services using serum-free proprietary medium for regenerative medicine applications, including treatments for chronic pain and joint conditions. Provided to medical institutions as contract manufacturing service.
  • BAMBANKER (Original) Original cell cryopreservation solution with 20+ years of market history. Serum-free formulation with no lot-to-lot variation, manufactured under GMP-compliant environment with ISO 9001 certified quality management. Sold domestically and internationally.
  • BAMBANKER Direct Cryopreservation solution allowing direct freezing without removing culture supernatant, simplifying the cell freezing workflow.
  • BAMBANKER hRM Cryopreservation solution for human ES/iPS cell research containing only pharmaceutical-grade albumin. Exclusively distributed by Japan Genetics Co., Ltd.
  • BAMBANKER DMSO free DMSO-free cryopreservation solution for users who wish to avoid DMSO exposure.
  • BAMBANKER iStock Cryopreservation solution with confirmed Regenerative Medicine Product Material Eligibility, designed for use as raw material in regenerative medicine product manufacturing.
  • iMediam for T Proprietary serum-free culture medium for efficient expansion of T cells and NK cells using patented technology (Patent No. 7144872). Has obtained Regenerative Medicine Product Material Qualification Confirmation. Manufactured under ISO 9001 quality management. Sold in Japan and exported to Korea, China, Taiwan. Used in Korean cell therapy pharmaceutical manufacturing and Taiwan clinical trials.
  • Activated Autologous Lymphocyte Therapy (Sekine Method) Cancer immunotherapy using the proprietary Sekine Method developed by Dr. Sekine at the National Cancer Center, involving T cell activation and expansion up to 50,000-fold using solid-phase CD3 antibody (OKT3). Composed of two phases: activation culture with OKT3 immobilized on vessel surface, followed by amplification culture. T cells retain cytotoxic activity against tumor cells. Over 4,000 patients treated in Japan over 25+ years.

Quantifiable outcome

  • T cell expansion of up to 50,000-fold in 2 weeks using the Sekine Method (vs. 10-100x for conventional IL-2 methods)
  • +8 more outcomes

Companies that use GC Lymphotec

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

GC Lymphotec technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

GC Lymphotec partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • 大中国際生醫集団 (Da Zhong International Biomedical Group, Taiwan)coreTechnology or Integration · 1 January 2014In 2014, GC Lymphotec entered into a technology licensing agreement with Taiwan's 大中国際生醫集団 for the technology transfer of activated autologous lymphocyte culture. The partnership enables the Taiwanese partner to manufacture and commercialize cell therapy products using GC Lymphotec's proprietary culture technology.
  • GC Cell Corporation (Korea)coreTechnology or Integration · 1 January 2005GC Lymphotec licensed its activated autologous lymphocyte culture technology to GC Cell Corporation in 2005. GC Cell used this technology to develop 'Immuncell-LC,' which received approval from the Korean Ministry of Food and Drug Safety (MFDS) in 2007 for hepatocellular carcinoma. The product also received US FDA Orphan Drug Designation in 2018. GC Cell has manufactured 80,000+ cumulative doses and treated 12,000+ patients in Korea. This is the company's flagship international licensing partnership and core source of overseas validation.
  • Fujifilm Wako Pure Chemical CorporationmajorChannel Partner/ Reseller/ DistributorMajor sales distributor for GC Lymphotec's cell culture reagents and cryopreservation solutions. Listed as one of the main sales channels alongside Japan Genetics and Cosmo Bio.
  • Japan Genetics Co., Ltd.majorChannel Partner/ Reseller/ DistributorExclusive distributor for BAMBANKER hRM (human ES/iPS research cryopreservation solution). Listed as one of the main sales channels alongside Fujifilm Wako Pure Chemical and Cosmo Bio.
  • Cosmo Bio Co., Ltd.majorChannel Partner/ Reseller/ DistributorMajor sales distributor for GC Lymphotec's cell culture reagents and cryopreservation solutions. Listed as one of the main sales channels alongside Fujifilm Wako Pure Chemical and Japan Genetics.
  • GC Group (GC Green Cross)coreStrategic or Co-development PartnerGC Lymphotec is a subsidiary of the GC Group (GC Green Cross), founded in 1967 and headquartered in Korea. GC Group is a leading Korean pharmaceutical company engaged in blood products, biopharmaceuticals, vaccines, diagnostics, and regenerative medicine. GC Group has subsidiaries in Korea, Japan, the United States, and Brazil, and actively serves markets in Asia, Middle East, and North/South America.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

GC Lymphotec competitors and assessment

Company assessment

Direct peers

  • MEDINET Co., Ltd. Japanese cell therapy CMO/CDMO offering immune cell processing services (T cells, NK cells, dendritic cells) for cancer immunotherapy under Japan's Regenerative Medicine Safety Act. Directly comparable in business model — autologous cell therapy manufacturing for affiliated Japanese clinics.
  • GC Cell Corporation: GC Lymphotec's Korean licensee and GC Group sibling company. Commercializes Immuncell-LC using licensed Sekine Method technology. Most directly comparable as a cell therapy product company using GC Lymphotec's own IP, providing reference economics for licensing validation.
  • STEMCELL Technologies Inc. Global leader in cell culture media, cryopreservation reagents (CryoStor, mFreSR), and stem cell research products. Directly comparable to GC Lymphotec's BAMBANKER and iMediam reagent product lines.

Broad incumbents

  • Takara Bio Inc. Japanese biotech with cell therapy, regenerative medicine, and cell processing reagent offerings. Comparable in cell culture media, cryopreservation reagents, and adjacent cell therapy services — overlaps with BAMBANKER and iMediam product lines.
  • JCR Pharmaceuticals Co., Ltd. Japanese specialty biopharma with regenerative medicine and cell therapy pipeline. Comparable as a Japan-domiciled player operating in adjacent cell/biologic therapy markets with GMP manufacturing capabilities.
  • Resonac Holdings (formerly Hitachi Chemical, Showa Denko Materials): Operates one of Japan's largest regenerative medicine CDMO businesses (formerly Hitachi Chemical Advanced Therapeutics Solutions). Comparable as a cell therapy contract manufacturer targeting the same Japanese regenerative medicine regulatory framework.
  • Lonza Group AG: Global leader in cell and gene therapy CDMO services. Comparable as a high-end cell therapy manufacturing services provider; provides benchmark for international CMO economics, scale, and pricing.
  • Miltenyi Biotec B.V. & Co. KG: Cell therapy manufacturing platform provider offering instruments, reagents, and GMP cell processing services. Comparable as a vertically integrated cell therapy manufacturing and reagent supplier serving CAR-T and NK cell developers globally.

Emerging players

  • StemRIM Inc. Japanese regenerative medicine company developing stem cell-based therapies (PELICAN). Comparable as a Japan-based, Japan-Regenerative-Medicine-Act-regulated cell therapy developer competing for similar affiliated clinic distribution.
  • Nikon CeLL innovation Co., Ltd. Nikon Group's cell therapy and regenerative medicine subsidiary operating GMP cell processing facilities in Japan. Comparable as a Japan-based cell therapy CMO with GMP manufacturing capacity targeting cancer immunotherapy and regenerative medicine.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

GC Lymphotec compliance and trust

Trust signal

Compliance3 records

GC Lymphotec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GC Lymphotec leadership team

Management profile

Number of profiles

Profiles2 records

GC Lymphotec funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GC Lymphotec M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GC Lymphotec

What does GC Lymphotec do?

GC Lymphotec provides contract cell therapy manufacturing (CMO) and contract quality control testing (CAS) for immune cell products, alongside proprietary cell culture reagents (BAMBANKER cryopreservation solutions, iMediam culture medium) and AI-powered cancer genetic tests (ai-CANCERCH screening, DNA CT monitoring). Services target medical institutions, biotech companies, and research organizations, with international technology licensing to Korea (GC Cell) and Taiwan.

Is GC Lymphotec a public or private company?

GC Lymphotec is a private company. It is classified as corporate owned and is currently operating.

When was GC Lymphotec founded?

GC Lymphotec was founded in 1999. It employs 251 to 500 people.

Where is GC Lymphotec based?

GC Lymphotec is headquartered in Koto, Japan, in the Asia region.

How does GC Lymphotec make money?

Seven revenue lines are on record. CMO — Cell Culture Contract Manufacturing is the primary driver. The others are CAS — Contract Testing Services, BAMBANKER Cryopreservation Solution Sales, iMediam Culture Medium Sales, ai-CANCERCH Genetic Testing, DNA CT Cancer Monitoring and technology Licensing.

Who are GC Lymphotec's main competitors?

Direct peers on record are MEDINET Co., Ltd., GC Cell Corporation and STEMCELL Technologies Inc.. Broad incumbents are Takara Bio Inc., JCR Pharmaceuticals Co., Ltd., Resonac Holdings (formerly Hitachi Chemical, Showa Denko Materials), Lonza Group AG and Miltenyi Biotec B.V. & Co. KG. Emerging players are StemRIM Inc. and Nikon CeLL innovation Co., Ltd..

Does GC Lymphotec have an API?

No public API is recorded for GC Lymphotec.

What industry is GC Lymphotec in?

GC Lymphotec's product category is Cell Therapy and Regenerative Medicine CDMO. Its primary akta.pro industry code is HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic), with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales